As shown in Table 1, by targeting MYB and inhibiting C-myb expression, this secretome suppresses NF-κB pathway activation and reduces the synthesis of type I collagen and alpha-smooth muscle actin, effectively impeding liver fibrosis progression. Here, NFKB1 is linked to Hepatic fibrosis.